Heparanase expression in blood is sensitive to monitor response to anticancer treatment in pancreatic cancer, a pilot study

Heparanase mRNA in PBMC and activity in plasma are closely correlated with therapeutic responsiveness and survival time, indicating that heparanase level in blood might be a sensitive but non-specific marker to monitor patients' response to anticancer treatment and to predict survival.